Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

INmune Bio, Inc. (INMB) vs Xilio Therapeutics, Inc. (XLO)

INmune Bio, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. INmune Bio, Inc. and Xilio Therapeutics, Inc. are of similar size ($59.2M and $55.5M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against −51.6%. INmune Bio, Inc. has the higher net margin (0.00% vs −34.1%) and the lower return on invested capital (−646.9% vs 0.00%). Across the 15 metrics below, Xilio Therapeutics, Inc. leads on 10 and INmune Bio, Inc. on 5.

Valuation

Metric INMB XLO Biotechnology median
P/E n/m n/m 7.88
P/S 401.77 2.74 11.47
P/B 2.66 2.43 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 301.47 0.75 10.73
Earnings yield (33.00%) (16.49%) (28.84%)
Free cash flow yield (30.30%) (34.93%) (23.03%)

Profitability

Metric INMB XLO Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity (74.82%) (55.03%) (57.72%)
Return on assets (57.08%) (15.16%) (49.22%)
Return on invested capital (646.94%) 0.00% 0.00%

Growth

Metric INMB XLO Biotechnology median
Revenue growth (TTM) (51.61%) 327.25% 5.64%
EPS growth (last fiscal year) 11.85% 72.55% —
Revenue growth, 5-year CAGR 35.37% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INMB XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.04 4.25 4.73
Net debt to EBITDA 0.52 3.40 0.96

Dividend

Metric INMB XLO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric INMB XLO Biotechnology median
Market cap 55.51m 59.22m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack